The results of these studies are unpublished yet, but based on the findings of previous studies, treatment with DS8201 could be a valuable therapy option with the potential to address the T-DM1 insensitive breast cancer and other HER2 expressing cancers. This evidence concerns the gene ERBB2 and breast carcinoma.